Trades and observations from a British contrarian stock investor

This blog is not intended to give financial advice. Before investing, do your own research and consult your financial adviser if appropriate. The accuracy of any information included is not guaranteed and may be subject to conjecture or interpretation by Contrarian Investor. Therefore visitors should validate all facts using alternative sources where possible.

Tuesday, March 23, 2010

GW Pharma announces positive clinical trial data in cancer pain

GW Pharma (GWP) announced today preliminary results of a Phase IIb dose-ranging trial evaluating the efficacy and safety of Sativex in the treatment of pain in patients with advanced cancer, who experience inadequate pain control during optimized chronic opioid therapy. 

This trial was performed in conjunction with GW's licensing partner for Sativex in the United States, Otsuka Pharmaceutical Co. Ltd..  In the US, cancer pain represents the initial target indication for Sativex. Key Points: - Study meets key objectives of providing data to support entry into Phase III - Sativex shows statistically significant differences from placebo in pain scores, according to both the continuous response analysis and change from baseline analysis in NRS average pain - GW and Otsuka now planning End of Phase II meeting with the FDA to gain endorsement of the proposed Phase III program 

Posted by Contrarian Investor UK at 7:13 AM
Labels: , ,

3 comments:

  1. AnonymousMarch 24, 2010 at 10:45 AM

    Well done on the blog ! i have been following your commentary and have invested in GWP based on your comments (after my own research of course ! Do you know if any of the big institutions have taken up a short position in GWP ? Just considering adding to my holding

    ReplyDelete
  2. Contrarian Investor UKMarch 24, 2010 at 10:56 AM

    Thank you and I'm pleased you've enjoyed reading the blog. Its been a good week courtesy of GWP.

    Unlike U.S. stocks, its difficult to know whether an institution is shorting a U.K. listing. I would be surprised if they are shorting GWP because the current market capitalisation of £152 million is not absurd compared with the enterprise value if you include the future potential earnings from the U.S. launch. Plus there is news flow to come in May - confirmation of end of decentralised regulatory phase and approval of national licence in U.K., approval of Spanish licence, start of mutual recognition etc.

    After selling, I have bought two new positions this morning on the SP weakness.

    ReplyDelete
  3. AnonymousApril 28, 2010 at 1:22 PM

    MAXIDEX DEXAMETHASONE WARNING

    I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS.

    Two days later I was BLIND

    Use Google and enter EPOCRATES MAXIDEX REACTION to verify

    Or call 800-757-9195

    ReplyDelete

Subscribe to: Post Comments (Atom)